Brokerage Firm Rating Update on Glaukos Corporation (GKOS)

Glaukos Corporation (GKOS) : 6 analysts are covering Glaukos Corporation (GKOS) and their average rating on the stock is 1.33, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Glaukos Corporation (GKOS) : Currently there are 4 street experts covering Glaukos Corporation (GKOS) stock. The most bullish and bearish price target for the stock is $42 and $40 respectively for the short term. The average price target of all the analysts comes to $41. The estimated standard deviation from the target is $0.82.


For the current week, the company shares have a recommendation consensus of Buy. Also, Roth Capital maintains its view on Glaukos Corporation (NYSE:GKOS) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Roth Capital raises the price target from $36.5 per share to $41 per share on Glaukos Corporation. The rating by the firm was issued on August 2, 2016.

Glaukos Corporation (NYSE:GKOS): stock was range-bound between the intraday low of $30.69 and the intraday high of $31.47 after having opened at $31.32 on Wednesdays session. The stock finally closed in the red at $31.32, a loss of -0.86%. The stock remained in the red for the whole trading day. The total traded volume was 464,745 shares. The stock failed to cross $31.47 in Wednesdays trading. The stocks closing price on Thursday was $31.26.

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eyes anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies, including three pipeline products, namely, the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.